Ge Long Hui A P P·2026-02-27 04:34Core Viewpoint - SystImmune, Inc. and Bristol Myers Squibb announced positive topline results from a pre-specified interim analysis of a Phase III clinical trial for izabren, demonstrating significant improvements in progression-free survival (PFS) and overall survival (OS) in patients with previously treated unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) [1][2]. Group 1: Clinical Trial Results - The Phase III study (BL-B01D1-307) achieved its dual primary endpoints, showing statistically and clinically significant improvements in PFS and OS compared to physician's choice of chemotherapy [1]. - Izabren is the first dual antibody-drug conjugate (ADC) to report positive results for both PFS and OS in a Phase III trial for TNBC globally [1]. Group 2: Ongoing Clinical Trials - As of January 2026, over 40 clinical trials for izabren are being conducted in collaboration with BMS, targeting various tumor types, including advanced TNBC and non-small cell lung cancer (NSCLC) [2]. - In China, Baili Tianheng is independently conducting 10 Phase III clinical registration studies for izabren across different cancer types, with 7 indications included in the breakthrough therapy designation by the National Medical Products Administration [2]. Group 3: Company Statements - Dr. Zhu Yi, founder and chairman of Baili Tianheng, expressed confidence in izabren's potential to provide significant clinical benefits for multiple tumor types, especially for patients with advanced TNBC who have limited treatment options [3]. - Cristian Massacesi, Executive Vice President and Chief Medical Officer at BMS, highlighted the potential of targeting EGFR×HER3 dual antibody-drug conjugates to improve outcomes in difficult-to-treat tumors, emphasizing ongoing scientific exploration and clinical development [3].